Vendome Acquisition 3Q 2026: Net income $1.68M — 10-Q Summary

Vendome Acquisition reported a 7.6% YoY decline in net income to $1.68M for 3Q 2026. The company has not started operations or generated revenue. It holds $209.1M in its trust account and has until July 3, 2027, to complete a business combination, per its SEC filing.

Original reporting
Published Nov 13, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vendome Acquisition 3Q 2026: Net income $1.68M — 10-Q Summary — source image
Decision brief

The 30-second read

$VNMEBearishLow
01

Why it matters

The earnings decline and ongoing uncertainty about a business combination increase short-term downside risk, but the sizable trust fund provides a cushion if a suitable target is found.

02

Market read

Primary disclosure of earnings and trust account status for a micro-cap SPAC; relevant for traders monitoring SPAC performance and merger prospects.

03

What to watch

Potential for a strategic acquisition that could dramatically improve the balance sheet and investor sentiment.

Relevance 5/10Novelty 5/10Timing: after-hours release

Background

Vendome Acquisition Corp I (VNME) filed its Q3 2026 10-Q, reporting a modest net loss and a large trust account balance while still searching for a merger target.

Company-level read

Ticker impact

$VNMEBearishMedium confidence
Context

10-Q filing shows Q3 net income of $1.68M, down 7.6% YoY, and trust account balance of $209.1M.

Expected impact

likely pressure as the market prices in the earnings decline and going-concern doubts

Evidence & confidence

The disclosed loss of momentum and the looming July 2027 combination deadline increase risk perception.

Market effects

SPAC sector may see heightened scrutiny as this filing highlights typical going-concern risks.

Limited to U.S. listed SPAC investors; no broader regional effect.

Minimal global impact; primarily relevant to niche SPAC traders.

Counterpoint

If the SPAC secures a high-quality target before the deadline, the trust fund could unlock significant upside.

Key entities

  • Vendome Acquisition Corp I

    Blank-check company (SPAC) seeking a merger target.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.